Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
1. Securities class action lawsuit filed against Kyverna Therapeutics. 2. Investors claim false statements made during the February 2024 IPO. 3. Misleading information involved adverse clinical trial data. 4. Lead plaintiff deadline is set for February 7, 2025.